000			06243cam a2200745Ki 4500
001			9781315269214
003			FlBoTFG
005			20220711212834.0
006			m o d
007			cr cnu---unuuu
008			180921s2018 flu ob 001 0 eng d
040			_aOCoLC-P _beng _erda _epn _cOCoLC-P
020			_a9781315269214 _q(electronic bk.)
020			_a131526921X _q(electronic bk.)
020			_a9781351978378
020			_a1351978373
020			_a9781351978354 _q(electronic bk. : Mobipocket)
020			_a1351978357 _q(electronic bk. : Mobipocket)
020			_a9781351978361 _q(electronic bk. : EPUB)
020			_a1351978365 _q(electronic bk. : EPUB)
020			_z9781138035157
020			_z1138035157
035			_a(OCoLC)1053888280 _z(OCoLC)1053868968
035			_a(OCoLC-P)1053888280
050		4	_aRC271.C5
072		7	_aHEA _x039000 _2bisacsh
072		7	_aMED _x014000 _2bisacsh
072		7	_aMED _x022000 _2bisacsh
072		7	_aMED _x112000 _2bisacsh
072		7	_aMED _x045000 _2bisacsh
072		7	_aMED _x071000 _2bisacsh
072		7	_aMED _x072000 _2bisacsh
072		7	_aTEC _x027000 _2bisacsh
072		7	_aTDCW _2bicssc
082	0	4	_a616.99/4061 _223
245	0	0	_aMolecular medicines for cancer : _bconcepts and applications of nanotechnology / _c[edited by] Deepak Chitkara, Anupama Mittal and Ram I. Mahato.
264		1	_aBoca Raton : _bCRC Press, _c[2018]
300			_a1 online resource (pages)
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
505	0		_aCover; Half Title; Title Page; Copyright Page; Dedication; Table of Contents; Foreword; Preface; Acknowledgments; Editors; Contributors; Section I : Nanotechnology-Based Approaches to Target Cancer; Chapter 1: Nanomedicines for Cancer; 1.1 Introduction; 1.2 Nanomedicines in Clinical Use and Under Clinical Trials; 1.2.1 Liposome-Based Nanomedicines; 1.2.2 Polymer-Based Nanomedicines; 1.2.3 Protein-Based Nanomedicines; 1.2.4 Micelles-Based Nanomedicines; 1.2.5 Nanotechnology-Based Miscellaneous Nanomedicines; 1.3 Targeting Mechanism of Nanomedicines; 1.3.1 Passive Targeting
505	8		_a1.3.2 Active Targeting1.3.3 Stimuli-Responsive Nanomedicine; 1.4 Design Aspect of Nanomedicines; 1.4.1 Vascular Transport; 1.4.2 Transvascular Transport; 1.4.3 Interstitial Transport; 1.4.4 Intracellular Transport; 1.5 Enhancing Nanomedicine Translation through Clinically Relevant Models; 1.5.1 Standard Xenograft Models with Human Stroma Components; 1.5.2 Patient-Derived Tumor Xenograft (PDX) Model; 1.5.3 Humanized PDX Model; 1.5.4 Human Metastatic Site Model; 1.6 Challenges and Current Limitations; 1.7 Advantages and Disadvantages of Nanotechnology; 1.8 Conclusion; References
505	8		_aChapter 2: Effect of Nanocarrier Size/Surface on Molecular Targeting in Cancer2.1 Introduction; 2.2 Particle Size in Tumor Targeting; 2.2.1 Tumor Type and Pore Cutoff Size; 2.2.2 Circulation in Bloodstream; 2.2.3 Nanoparticle Trafficking and Tumor Internalization; 2.2.4 Cellular Uptake and Cell-Particle Interactions; 2.3 Particle Shape on Tumor Targeting; 2.3.1 Circulation in Bloodstream; 2.3.2 Nanoparticle Transportation and Tumor Internalization; 2.3.3 Cellular Uptake and Cell-Particle Interactions; 2.4 Influence of Nanocarrier Surface Properties on Tumor Targeting
505	8		_a2.4.1 Circulation in Bloodstream2.4.2 Nanoparticle Transportation and Tumor Internalization; 2.4.3 Surface Functionalization with Targeting Tumors; 2.5 Conclusion; References; Chapter 3: Nanocarrier Systems for Anticancer Drug Delivery at the Subcellular Level; 3.1 Introduction; 3.2 Mitochondrial Targeted Drug Delivery; 3.2.1 Mitochondria and Cancer Therapy; 3.2.2 Mitochondrial Drug Delivery; 3.2.2.1 Mitochondriotropic Conjugated Nanocarriers; 3.2.2.2 Mitochondrial-Penetrating Peptide (MPP) Conjugated Nanocarriers; 3.2.2.3 Mitochondrial Targeting Signal (MTS) Conjugated Nanocarriers
505	8		_a3.3 Nuclear Targeted Drug Delivery3.3.1 The Nucleus: Role in Cancer Treatment; 3.3.2 Nuclear Drug Delivery; 3.3.2.1 Nuclear Localization Signal (NLS) Conjugated Nanocarriers; 3.3.2.2 Other Approaches; 3.4 Lysosomal Targeted Drug Delivery; 3.4.1 Lysosomes; 3.4.2 Lysosomal Cell Death; 3.4.3 Lysosomal Drug Delivery; 3.4.3.1 Nanocarriers Containing Lysosomotropic Agents; 3.4.3.2 Nanocarriers Modified with Cathepsin-Specific Substrates; 3.4.3.3 Ceramide Containing Nanocarriers; 3.4.3.4 Metal Nanoparticles; 3.4.3.5 pH-Responsive Nanocarriers; 3.5 Endoplasmic Reticulum (ER) Targeted Drug Delivery
520			_aThe field of molecular medicine covers the medical interventions targeting molecular structures and mechanisms that are involved in disease progression. In cancer, several molecular mechanisms have been shown to impact its progression, aggressiveness and chemoresistance. Increasing evidence demonstrates the role of nanotechnology and outcome of molecular therapy. Several books have discussed molecular biology and mechanisms involved in cancer, but this text gives an account of molecular therapeutics in cancer relating to advancements of nanotechnology. It provides a description of the multidisciplinary field of molecular medicines and its targeted delivery to cancer using nanotechnology.
588			_aOCLC-licensed vendor bibliographic record.
650		0	_aTumors. _911942
650		0	_aChemotherapy. _920073
650		7	_aHEALTH & FITNESS / Diseases / General _2bisacsh _98806
650		7	_aMEDICAL / Clinical Medicine _2bisacsh _98807
650		7	_aMEDICAL / Diseases _2bisacsh _98808
650		7	_aMEDICAL / Evidence-Based Medicine _2bisacsh _98809
650		7	_aMEDICAL / Internal Medicine _2bisacsh _98810
650		7	_aMEDICAL / Pharmacology _2bisacsh _97291
650		7	_aMEDICAL / Pharmacy _2bisacsh _920074
650		7	_aTECHNOLOGY / Nanotechnology _2bisacsh _912200
700	1		_aChitkara, Deepak, _eeditor. _920075
700	1		_aMittal, Anupama, _eeditor. _920076
700	1		_aMahato, Ram I., _eeditor. _920077
856	4	0	_3Taylor & Francis _uhttps://www.taylorfrancis.com/books/9781315269214
856	4	2	_3OCLC metadata license agreement _uhttp://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf
942			_cEBK
999			_c72278 _d72278